| 4 | CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S) Ann Surg Oncol 2023 May;30(5):3013-3021 |
| 1 | The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505. (Evans DB) Ann Surg 2020 Sep 01;272(3):487 8 Citations |
| 1 | Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. (Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ) Clin Cancer Res 2020 Sep 15;26(18):4814-4822 52 Citations |
| 1 | Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. (Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA) Clin Cancer Res 2020 Mar 15;26(6):1338-1348 22 Citations |
| 1 | Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. (Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC) Ann Surg Oncol 2019 Dec;26(13):4489-4497 17 Citations |
| 1 | Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. (Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, Ahmad SA, Patel SH, Abbott DE, Schwartz P, Weber SM, Scoggins CR, Martin RCG, Dudeja V, Franceschi D, Livingstone AS, Merchant NB) Ann Surg 2019 Sep;270(3):400-413 91 Citations |
| 1 | Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. (Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D) Br J Cancer 2018 May;118(11):1419-1424 4 Citations |
| 2 | Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? (Jethava Y, Guru Murthy GS, Hamadani M) Hematol Oncol Stem Cell Ther 2017 Jun;10(2):47-56 7 Citations |
| 1 | Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. (Eng KH, Hanlon BM, Bradley WH, Szender JB) Gynecol Oncol 2015 Nov;139(2):228-35 18 Citations |
| 1 | Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. (Reese JA, Bougie DW, Curtis BR, Terrell DR, Vesely SK, Aster RH, George JN) Am J Hematol 2015 May;90(5):406-10 75 Citations |
| 1 | Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. (Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH) Ann Surg Oncol 2015 Jul;22(7):2416-23 111 Citations |
| 2 | Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 29 Citations |
| 1 | Gemcitabine transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. (Hammond JS, Franko J, Holloway SE, Heckman JT, Orons PD, Gamblin TC) Hepatogastroenterology 2014;61(133):1339-43 12 Citations |
| 1 | A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. (Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM) BMC Cancer 2014 Aug 02;14:561 12 Citations |
| 4 | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. (Cheng G, Zielonka J, McAllister D, Tsai S, Dwinell MB, Kalyanaraman B) Br J Cancer 2014 Jul 08;111(1):85-93 66 Citations |
| 2 | Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. (Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J) J Thorac Oncol 2014 May;9(5):702-9 38 Citations |
| 1 | CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. (Colbert LE, Petrova AV, Fisher SB, Pantazides BG, Madden MZ, Hardy CW, Warren MD, Pan Y, Nagaraju GP, Liu EA, Saka B, Hall WA, Shelton JW, Gandhi K, Pauly R, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Curran WJ Jr, Landry JC, Maithel SK, Yu DS) Cancer Res 2014 May 15;74(10):2677-87 29 Citations |
| 7 | Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 160 Citations |
| 1 | Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. (Hall WA, Petrova AV, Colbert LE, Hardy CW, Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Volkan Adsay N, Curran WJ, Landry JC, Maithel SK, Yu DS) Oncogene 2014 Nov 20;33(47):5450-6 17 Citations |
| 1 | Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. (Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH) J Gastrointest Surg 2014 Jan;18(1):16-24; discussion 24-5 152 Citations |
| 2 | Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. (Zimmerman NP, Roy I, Hauser AD, Wilson JM, Williams CL, Dwinell MB) Mol Carcinog 2015 Mar;54(3):203-15 40 Citations |
| 2 | Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. (Cano CE, Hamidi T, Garcia MN, Grasso D, Loncle C, Garcia S, Calvo E, Lomberk G, Dusetti N, Bartholin L, Urrutia R, Iovanna JL) Gut 2014 Jun;63(6):984-95 32 Citations |
| 2 | Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs. (Gilabert M, Vaccaro MI, Fernandez-Zapico ME, Calvo EL, Turrini O, Secq V, Garcia S, Moutardier V, Lomberk G, Dusetti N, Urrutia R, Iovanna JL) J Cell Physiol 2013 Sep;228(9):1834-43 10 Citations |
| 1 | Potent methyl oxidation of 5-methyl-2'-deoxycytidine by halogenated quinoid carcinogens and hydrogen peroxide via a metal-independent mechanism. (Shao J, Huang CH, Kalyanaraman B, Zhu BZ) Free Radic Biol Med 2013 Jul;60:177-82 41 Citations |
| 1 | A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. (Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R) Invest New Drugs 2013 Aug;31(4):918-26 28 Citations |
| 1 | Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. (Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R) Cancer Chemother Pharmacol 2012 May;69(5):1117-26 11 Citations |
| 1 | The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. (Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S, A5217 Study Team) J Infect Dis 2012 Jan 01;205(1):87-96 92 Citations |
| 2 | Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 60 Citations |
| 1 | Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). (Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV) Invest Radiol 2012 Jan;47(1):11-7 131 Citations |
| 1 | Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report. (Cole PD, McCarten KM, Drachtman RA, Alarcon Pd, Chen L, Trippett TM, Schwartz CL) Pediatr Hematol Oncol 2010 Nov;27(8):650-7 2 Citations |
| 1 | HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. (Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK) Ann Surg 2010 Sep;252(3):499-505; discussion 505-6 88 Citations |
| 1 | A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. (Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL) Clin Colorectal Cancer 2010 Jul;9(3):157-61 6 Citations |
| 1 | Salirasib in the treatment of pancreatic cancer. (Bustinza-Linares E, Kurzrock R, Tsimberidou AM) Future Oncol 2010 Jun;6(6):885-91 40 Citations |
| 2 | Management of borderline resectable pancreatic cancer. (Lal A, Christians K, Evans DB) Surg Oncol Clin N Am 2010 Apr;19(2):359-70 9 Citations |
| 1 | Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. (Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH) Int J Radiat Oncol Biol Phys 2010 May 01;77(1):60-5 86 Citations |
| 1 | Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. (Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA) Cancer J 2009;15(4):339-43 42 Citations |
| 1 | A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. (Bekaii-Saab T, Hill M, Campbell A, Kosuri K, Thomas J, Villalona-Calero M) Cancer Chemother Pharmacol 2010 Apr;65(5):863-9 |
| 3 | Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. (George B, Wirostko WJ, Connor TB, Choong NW) J Thorac Oncol 2009 May;4(5):661-2 33 Citations |
| 1 | Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. (Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS) Oncology 2009;76(5):333-7 21 Citations |
| 1 | Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. (Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM) J Clin Oncol 2009 Mar 20;27(9):1456-61 46 Citations |
| 1 | The integration of chemoradiation in the care of patient with localized pancreatic cancer. (Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA) Cancer Radiother 2009 Apr;13(2):123-43 15 Citations |
| 1 | A phase I study of an oral simulated FOLFOX with high dose capecitabine. (Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G) Invest New Drugs 2009 Oct;27(5):461-8 7 Citations |
| 1 | Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. (Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML) Ann Surg Oncol 2009 Feb;16(2):431-9 40 Citations |
| 1 | Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB) J Clin Oncol 2008 Jul 20;26(21):3487-95 410 Citations |
| 1 | Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA) J Clin Oncol 2008 Jul 20;26(21):3496-502 644 Citations |
| 1 | Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. (Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D) Clin Cancer Res 2008 Apr 01;14(7):2042-8 44 Citations |
| 1 | Cancer-associated stromal fibroblasts promote pancreatic tumor progression. (Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD) Cancer Res 2008 Feb 01;68(3):918-26 879 Citations |
| 1 | A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. (Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G) Cancer Chemother Pharmacol 2008 Sep;62(4):727-33 10 Citations |
| 1 | Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. (Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL) Cancer Chemother Pharmacol 2008 Sep;62(4):647-53 17 Citations |
| 1 | Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. (Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW) Int J Radiat Oncol Biol Phys 2008 Mar 01;70(3):735-43 64 Citations |
| 1 | Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. (Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, Gamblin TC) J Gastrointest Surg 2008 Jan;12(1):129-37 104 Citations |
| 1 | Future chemoradiation strategies in pancreatic cancer. (Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA) Semin Oncol 2007 Aug;34(4):335-46 28 Citations |
| 1 | Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. (Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH) Cancer 2007 Jul 01;110(1):47-55 229 Citations |
| 1 | Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. (Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI) Int J Radiat Oncol Biol Phys 2007 Jun 01;68(2):472-8 131 Citations |
| 1 | Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. (Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH) Cancer 2006 Dec 01;107(11):2589-96 75 Citations |
| 1 | Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. (Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME, Krishnan S, Janjan NA, Crane CH) Radiat Oncol 2006 Oct 24;1:41 20 Citations |
| 1 | Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. (Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N) Clin Lymphoma Myeloma 2006 Jul;7(1):51-8 141 Citations |
| 1 | Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA) Cancer 2006 Jul 01;107(1):83-9 123 Citations |
| 1 | Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. (Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS) Gynecol Oncol 2006 Nov;103(2):489-93 93 Citations |
| 1 | The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB) Best Pract Res Clin Gastroenterol 2006 Apr;20(2):365-82 43 Citations |
| 1 | Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. (Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL) J Clin Oncol 2006 Apr 10;24(11):1720-8 126 Citations |
| 1 | Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA) J Clin Oncol 2006 Mar 01;24(7):1145-51 195 Citations |
| 1 | Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. (Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI) J Clin Oncol 2006 Feb 01;24(4):656-62 128 Citations |
| 1 | A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. (Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP) Oncology 2005;69(2):130-4 15 Citations |
| 1 | Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. (Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE, Ellis LM) Br J Cancer 2005 Jul 25;93(2):233-41 97 Citations |
| 1 | Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. (Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB 3rd) Oncology 2004;66(4):303-9 34 Citations |
| 1 | Gemcitabine, Paclitaxel, and piritrexim: a phase I study. (Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP) Am J Clin Oncol 2003 Jun;26(3):280-4 5 Citations |
| 1 | Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. (Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PW, Evans DB, Killion JJ, Fidler IJ) Clin Cancer Res 2003 May;9(5):1858-67 36 Citations |
| 1 | Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. (Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ) J Gastrointest Surg 2003 Jan;7(1):37-43; discussion 43 65 Citations |
| 1 | Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. (Crane CH, Antolak JA, Rosen II, Forster KM, Evans DB, Janjan NA, Charnsangavej C, Pisters PW, Lenzi R, Papagikos MA, Wolff RA) Int J Gastrointest Cancer 2001;30(3):123-32 56 Citations |
| 1 | Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. (Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G) Invest New Drugs 2002 Nov;20(4):377-82 1 Citation |
| 1 | Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. (Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL) Ann Oncol 2002 Nov;13(11):1819-25 7 Citations |
| 1 | Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. (Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd) J Clin Oncol 2002 Aug 01;20(15):3270-5 704 Citations |
| 1 | Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? (Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA) Int J Radiat Oncol Biol Phys 2002 Apr 01;52(5):1293-302 197 Citations |
| 1 | Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. (Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL) Int J Pancreatol 2001;29(1):9-18 73 Citations |
| 1 | Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. (Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA) Semin Oncol 2001 Jun;28(3 Suppl 10):25-33 57 Citations |
| 1 | Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. (Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL) Clin Cancer Res 2001 Aug;7(8):2246-53 185 Citations |
| 1 | Neoadjuvant strategies for pancreatic cancer. (Evans DB, Wolff RA, Crane CH) Oncology (Williston Park) 2001 Jun;15(6):727-37; discussion 741-4, 747 13 Citations |
| 1 | Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. (Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2001 Mar;8(2):123-32 315 Citations |
| 1 | Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. (Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R) Clin Cancer Res 2000 May;6(5):1936-48 423 Citations |
| 1 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB) J Clin Oncol 2000 Feb;18(4):860-7 80 Citations |
| 1 | Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. (Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS) Gynecol Oncol 2000 Feb;76(2):204-7 81 Citations |
| 1 | Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. (Wong SJ, Myette MS, Wereley JP, Chitambar CR) Clin Cancer Res 1999 Feb;5(2):439-43 20 Citations |
